News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
310,143 Results
Type
Article (15408)
Company Profile (282)
Press Release (294453)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (91539)
Career Advice (161)
Deals (16167)
Drug Delivery (35)
Drug Development (53671)
Employer Resources (31)
FDA (6860)
Job Trends (5545)
News (165060)
Policy (12317)
Tag
Academia (962)
Accelerated approval (2)
Adcomms (12)
Allergies (57)
Alliances (26104)
ALS (71)
Alzheimer's disease (905)
Antibody-drug conjugate (ADC) (110)
Approvals (6902)
Artificial intelligence (139)
Autoimmune disease (19)
Automation (5)
Bankruptcy (111)
Best Places to Work (4796)
BIOSECURE Act (6)
Biosimilars (53)
Biotechnology (235)
Bladder cancer (62)
Brain cancer (20)
Breast cancer (177)
Cancer (1598)
Cardiovascular disease (122)
Career advice (142)
Career pathing (2)
CAR-T (123)
Cell therapy (346)
Cervical cancer (9)
Clinical research (43960)
Collaboration (589)
Compensation (284)
Complete response letters (13)
COVID-19 (1119)
CRISPR (44)
C-suite (180)
Cystic fibrosis (78)
Data (1676)
Denatured (11)
Depression (33)
Diabetes (147)
Diagnostics (1746)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (87)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (92)
Earnings (34519)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (52723)
Executive appointments (496)
FDA (7705)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (534)
Gene editing (102)
Generative AI (10)
Gene therapy (275)
GLP-1 (396)
Government (1205)
Grass and pollen (3)
Guidances (76)
Healthcare (7136)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (21)
Infectious disease (1191)
Inflammatory bowel disease (124)
Inflation Reduction Act (8)
Influenza (26)
Intellectual property (75)
Interviews (18)
IPO (8117)
IRA (11)
Job creations (1041)
Job search strategy (135)
Kidney cancer (7)
Labor market (8)
Layoffs (219)
Leadership (3)
Legal (2136)
Liver cancer (43)
Lung cancer (219)
Lymphoma (107)
Machine learning (5)
Management (7)
Manufacturing (160)
MASH (67)
Medical device (3532)
Medtech (3534)
Mergers & acquisitions (8438)
Metabolic disorders (421)
Multiple sclerosis (58)
NASH (13)
Neurodegenerative disease (75)
Neuropsychiatric disorders (25)
Neuroscience (1343)
NextGen: Class of 2025 (2138)
Non-profit (891)
Now hiring (22)
Obesity (203)
Opinion (103)
Ovarian cancer (67)
Pain (48)
Pancreatic cancer (65)
Parkinson's disease (126)
Partnered (9)
Patents (143)
Patient recruitment (84)
Peanut (35)
People (28246)
Pharmaceutical (47)
Pharmacy benefit managers (6)
Phase I (15193)
Phase II (20263)
Phase III (13222)
Pipeline (979)
Policy (49)
Postmarket research (991)
Preclinical (6390)
Press Release (32)
Prostate cancer (67)
Psychedelics (35)
Radiopharmaceuticals (222)
Rare diseases (304)
Real estate (1871)
Recruiting (12)
Regulatory (10190)
Reports (19)
Research institute (981)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (65)
Series A (102)
Series B (70)
Service/supplier (1)
Sickle cell disease (42)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (2182)
State (1)
Stomach cancer (5)
Supply chain (24)
Tariffs (12)
The Weekly (37)
Vaccines (233)
Venture capitalists (33)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (123)
Last 7 days (631)
Last 30 days (1918)
Last 365 days (20494)
2025 (7415)
2024 (21855)
2023 (23966)
2022 (30247)
2021 (31137)
2020 (26590)
2019 (18341)
2018 (13441)
2017 (15635)
2016 (13739)
2015 (16812)
2014 (12452)
2013 (9312)
2012 (9526)
2011 (9706)
2010 (9313)
Location
Africa (195)
Alabama (43)
Alaska (2)
Arizona (59)
Arkansas (5)
Asia (30212)
Australia (4394)
California (4168)
Canada (1258)
China (433)
Colorado (152)
Connecticut (157)
Delaware (111)
Europe (44811)
Florida (504)
Georgia (127)
Idaho (16)
Illinois (247)
India (14)
Indiana (95)
Iowa (2)
Japan (136)
Kansas (67)
Kentucky (5)
Louisiana (3)
Maine (13)
Maryland (531)
Massachusetts (3362)
Michigan (75)
Minnesota (174)
Mississippi (1)
Missouri (26)
Montana (14)
Nebraska (4)
Nevada (18)
New Hampshire (14)
New Jersey (1086)
New Mexico (12)
New York (1132)
North Carolina (586)
North Dakota (5)
Northern California (1854)
Ohio (115)
Oklahoma (9)
Oregon (22)
Pennsylvania (784)
Puerto Rico (6)
Rhode Island (19)
South America (273)
South Carolina (5)
Southern California (1600)
Tennessee (25)
Texas (476)
United States (14376)
Utah (65)
Virginia (83)
Washington D.C. (32)
Washington State (362)
Wisconsin (20)
310,143 Results for "enlivex therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
April 23, 2025
·
4 min read
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Therapeutics Ltd. is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m. ET.
June 20, 2024
·
4 min read
Deals
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares.
May 28, 2024
·
6 min read
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares and clinical milestone-linked warrants.
May 29, 2024
·
5 min read
Press Releases
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
March 4, 2025
·
4 min read
Press Releases
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
March 18, 2025
·
5 min read
Press Releases
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
April 21, 2025
·
5 min read
Press Releases
Join Enlivex Therapeutics’ Exclusive Live Investor Webinar and Q&A Session on December 3
November 27, 2024
·
3 min read
Drug Development
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today released a positive interim data readout from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who had been indicated for knee replacement surgery.
June 17, 2024
·
7 min read
Drug Development
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics Ltd. today announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I/II trial evaluating the efficacy and safety of Allocetra™ following injection into patients with basal thumb joint (first carpometacarpal (CMC) joint) osteoarthritis, for which conventional therapies have failed.
June 24, 2024
·
5 min read
1 of 31,015
Next
